Uncategorized

NRx Pharmaceuticals, Inc., a clinical-stage CNS biopharmaceutical company, reported that the independent Data Safety Monitoring Board reviewed the safety and efficacy findings of the first fifty enrolled participants in the Company’s clinical trial of NRX-101 for the treatment of Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior.

People who dedicate their careers to healthcare often do so because of a deep desire to help others.

Learn how to help address common printing challenges, manage the breadth of printed materials required for internal and external communications and reduce costs.

Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali® plus endocrine therapy in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer at risk of recurrence.

Biophytis SA announced that it has held a presentation on their drug candidate, Sarconeos, as a possibility to cure long COVID after hospitalization, at the 13th annual International Conference on Frailty and Sarcopenia Research.

BioInvent International The shareholders of BioInvent International AB, Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 27 April 2023 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.

Incyte announced that the Japanese Ministry of Health, Labour and Welfare has approved Pemazyre®, a selective fibroblast growth factor receptor inhibitor, for the treatment of myeloid/lymphoid neoplasms with FGFR1 fusion.

Ionis Pharmaceuticals, Inc. announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca’s eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy, a debilitating and potentially fatal disease that leads to peripheral nerve damage and motor disability.

Everest Medicines announced that it has received full upfront payment of $280 million from Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc., for the transaction around Trodelvy® rights in certain Asia territories.

Short-term safety was confirmed. Efficacy including visual acuity and corneal thickness is improving.